These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 10892137)

  • 1. [Indications for the use of granulocyte growth factors].
    Elonen E
    Duodecim; 1997; 113(22):2319-25. PubMed ID: 10892137
    [No Abstract]   [Full Text] [Related]  

  • 2. The role of granulocyte colony-stimulating factor with dose-intensive chemotherapy.
    Ogawa M
    Semin Oncol; 1994 Feb; 21(1 Suppl 1):7-9. PubMed ID: 7512279
    [No Abstract]   [Full Text] [Related]  

  • 3. [Hematopoietic growth factors in the treatment of acute myeloblastic leukemia].
    de la Rubia Comos J
    Sangre (Barc); 1997 Apr; 42 Suppl 1():32-3. PubMed ID: 9381298
    [No Abstract]   [Full Text] [Related]  

  • 4. Should the indications for the use of myeloid growth factors for the prevention of febrile neutropenia in cancer patients be extended?
    Klastersky J; Awada A; Aoun M; Paesmans M
    Curr Opin Oncol; 2009 Jul; 21(4):297-302. PubMed ID: 19509500
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Filgrastim--a hematopoietic growth factor (r-metHuC-CSF) for treatment of neutropenia caused by cytostatics].
    Ersbøll J
    Ugeskr Laeger; 1991 Sep; 153(38):2647-50. PubMed ID: 1719682
    [No Abstract]   [Full Text] [Related]  

  • 6. Meta-analysis of randomized controlled trials of granulocyte colony-stimulating factor prophylaxis in adult cancer patients receiving chemotherapy.
    Kuderer NM
    Cancer Treat Res; 2011; 157():127-43. PubMed ID: 21052954
    [No Abstract]   [Full Text] [Related]  

  • 7. Prophylactic granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor decrease febrile neutropenia after chemotherapy in children with cancer: a meta-analysis of randomized controlled trials.
    Sung L; Nathan PC; Lange B; Beyene J; Buchanan GR
    J Clin Oncol; 2004 Aug; 22(16):3350-6. PubMed ID: 15310780
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The American Society of Clinical Oncology guideline program.
    Winn RF; Smith TF
    Pharm Pract Manag Q; 1996 Apr; 16(1):31-8. PubMed ID: 10157738
    [No Abstract]   [Full Text] [Related]  

  • 9. Granulocyte colony-stimulating factors in the management of chemotherapy-induced neutropenia: evidence based review.
    Bhana N
    Curr Opin Oncol; 2007 Jul; 19(4):328-35. PubMed ID: 17545795
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Granulocyte colony-stimulating factors as a support therapy in malignant diseases].
    Riikonen P; Elonen E; Teerenhovi L
    Duodecim; 2002; 118(21):2249-54. PubMed ID: 12486962
    [No Abstract]   [Full Text] [Related]  

  • 11. [The dilemma of stimulating factors in the recovery from chemotherapeutic neutropenia].
    Borbollo Escoboza JR; González Avante M; Alvarado Ibarra M
    Rev Invest Clin; 1996; 48(4):328. PubMed ID: 8966397
    [No Abstract]   [Full Text] [Related]  

  • 12. Granulocyte colony-stimulating factor in afebrile patients with neutropenia.
    Cabanillas F
    N Engl J Med; 1997 Oct; 337(18):1319-20. PubMed ID: 9380086
    [No Abstract]   [Full Text] [Related]  

  • 13. Growth factor frenzy.
    Quesenberry PJ
    Exp Hematol; 1993 Jul; 21(7):835-6. PubMed ID: 7686499
    [No Abstract]   [Full Text] [Related]  

  • 14. A tale of two growth factors.
    Fruehauf JP; Kong KM; Wong SF; Chan HO
    Pharmacotherapy; 2006 Mar; 26(3):443-4; discussion 444. PubMed ID: 16503728
    [No Abstract]   [Full Text] [Related]  

  • 15. Prophylactic use of granulocyte colony-stimulating factor after chemotherapy does not affect survival rate in acute myeloid leukemia: a meta-analysis.
    Wang J; An L; Chen S; Ouyang J; Zhou R; Chen B; Yang Y
    Acta Haematol; 2009; 121(4):223-6. PubMed ID: 19546524
    [No Abstract]   [Full Text] [Related]  

  • 16. Effects of a formulary change from granulocyte colony-stimulating factor to granulocyte-macrophage colony-stimulating factor on outcomes in patients treated with myelosuppressive chemotherapy.
    Wong SF; Chan HO
    Pharmacotherapy; 2005 Mar; 25(3):372-8. PubMed ID: 15843284
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Filgrastim--human granulocyte-colony stimulating factor.
    Drug Ther Bull; 1993 Apr; 31(9):33-6. PubMed ID: 7688277
    [No Abstract]   [Full Text] [Related]  

  • 18. [Preventing and treating hematologic complications of anticancer chemotherapy: update on hematopoietic growth factors].
    Spaëth D; Geoffrois L; Conroy T
    Bull Cancer; 2000 Jan; 87(1):93-6. PubMed ID: 10673637
    [No Abstract]   [Full Text] [Related]  

  • 19. [Clinical administration of hematopoietic growth factors. When and where?].
    Ottmann OG; Seipelt G; Hoelzer D
    Internist (Berl); 1997 Dec; 38(12):1160-7. PubMed ID: 9465321
    [No Abstract]   [Full Text] [Related]  

  • 20. Thrombosis in cancer patients treated with hematopoietic growth factors--a meta-analysis. On behalf of the Subcommittee on Haemostasis and Malignancy of the Scientific and Standardization Committee of the ISTH.
    Barbui T; Finazzi G; Grassi A; Marchioli R
    Thromb Haemost; 1996 Feb; 75(2):368-71. PubMed ID: 8815592
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.